NICE approves Rituxan for first-line treatment of follicular lymphoma


In a coup for Roche and a victory for follicular lymphoma patients in the United Kingdom, Rituxan (known in the UK as MabThera) has been approved for use on the UK's National Health Service for the first-line treatment of follicular lymphoma.

The approval comes after months of consideration given by the National Institute for Health and Clinical Excellence (NICE).

Prior to this, Rituxan was only approved for UK follicular lymphoma patients if their disease had returned. Now, they may receive it in a maintenance setting as a first-line therapy.

Source: Dow Jones Newswires

LymphomaInfo Social